Skip to main content
Figure 5 | Cardiovascular Diabetology

Figure 5

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 5

Effects of long-term (10 weeks) empagliflozin administration on non-fasting blood glucose (A), oral glucose tolerance test (B), serum insulin levels (C), and body weight (D) of db/db mice. Abbreviations: db/m, non-diabetic db/m mice; Control, control (untreated) db/db mice; Empa, empagliflozin-treated db/db mice. *p < 0.05, †p < 0.01, vs control db/db mice. Values are mean ± SEM (n = 9-11).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840